Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC)

被引：9
|
作者：
Szczylik, C.
Porta, C.
Bracarda, S.
Hawkins, R.
Bjarnason, G. A.
Oudard, S.
Lee, S.
Carteni, G.
Hariharan, S.
Gore, M. E.
机构：
[1] Mil Med Inst, Warsaw, Poland
[2] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy
[3] Azienda Osped Perugia, Perugia, Italy
[4] Christie Hosp, Manchester, Lancs, England
[5] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[6] Hop Europeen Georges Pompidou, Paris, France
[7] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[8] Pfizer Inc, New York, NY USA
[9] Royal Marsden Hosp NHS Trust, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5124
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Metastatic Renal Cell Carcinoma: Nephrectomy plus Sunitinib versus Sunitinib Alone
    Kroeger, Nils
    Bedke, Jens
    Burchardt, Martin
    AKTUELLE UROLOGIE, 2019, 50 (02) : 132 - 134
  • [42] Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis
    Josephs, D. H.
    Hutson, T. E.
    Pickering, L. M.
    Larkin, J. M.
    Choueiri, T. K.
    Patel, T. V.
    Mcdermott, D. F.
    Powles, T.
    Harper, P. G.
    Chowdhury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial
    Sternberg, Cora N.
    Calabro, Fabio
    Bracarda, Sergio
    Carteni, Giacomo
    Lo Re, Giovanni
    Ruggeri, Enzo M.
    Basso, Umberto
    Gasparini, Giampietro
    Ciuffreda, Libero
    Ferrari, Vittorio
    Bonetti, Andrea
    Fea, Elena
    Gasparro, Donatello
    Tassinari, Davide
    Labianca, Roberto
    Masini, Cristina
    Fly, Kolette
    Zhang, Ke
    Hariharan, Subramanian
    Capaccetti, Barbara
    Porta, Camillo
    ONCOLOGY, 2015, 88 (05) : 273 - 280
  • [44] Renal safety of sunitinib treatment: A prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Rixe, O.
    Meric, J. B.
    Alexandre, J.
    Goldwasser, F.
    Izzedine, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 36 - 36
  • [45] Safety and efficacy of sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of an Italian expanded-access program (EAP) with subpopulation analysis
    Stemberg, Cora N.
    Porta, Camillo
    Bracarda, Sergio
    Carteni, Giacomo
    Lo Re, Giovanni
    Ruggeri, Enzo M.
    Conte, Pierfranco
    Monfardini, Silvio
    Gasparini, Giampietro
    Ciuffreda, Libero
    Marini, Giovanni
    Bonetti, Andrea
    Heouaine, Abdhelhamid
    Bernardini, Ilaria
    Ravaioli, Alberto
    Labianca, Roberto
    JOURNAL OF UROLOGY, 2008, 179 (04): : 418 - 418
  • [46] Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Gordon, M. S.
    Stein, M.
    Shannon, P.
    Eddy, S.
    Tyler, A.
    Catlett, L.
    Hsyu, P.
    Huang, B.
    Healey, D.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Time from nephrectomy (Nx) as an independent prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapies (TTs)
    Procopio, Giuseppe
    Iacovelli, Roberto
    Verzoni, Elena
    Grassi, Paolo
    Testa, Isabella
    Garanzini, Enrico
    Nicolai, Nicola
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [48] Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
    Ghatalia, Pooja
    Handorf, Elizabeth A.
    Deng, Mengying
    Zibelman, Matthew R.
    Abbosh, Philip
    Anari, Fern
    Greenberg, Richard E.
    Viterbo, Rosalia
    Chen, David
    Smaldone, Marc C.
    Kutikov, Alexander
    Geynisman, Daniel M.
    Uzzo, Robert Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Billemont, B.
    Barete, S.
    Meric, J. B.
    Moguelet, P.
    Frances, C.
    Chosidow, O.
    Goldwasser, F.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [50] Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC)
    Urun, Yuksel
    Gray, Kathryn P.
    Signoretti, Sabina
    McDermott, David F.
    Atkins, Michael B.
    Lampron, Megan E.
    Freedman, Matthew
    Choueiri, Toni K.
    Pomerantz, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345